S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

World Class Health Expands Into Specialty Infusion Care

Specialty drugs now account for half of all pharmacy spending, with costs projected to rise by 32% by 2028. Seeking to curb these expenses, San Francisco-based World Class Health is launching a new infusion network that shifts treatments from expensive hospital outpatient suites to home settings or lower-cost facilities.

World Class Health Expands Into Specialty Infusion Care
Photo: Bio & News

The platform, which already coordinates surgery and imaging, now manages over 270 specialty infusions. By moving care out of hospitals, the company reports that employers can save an average of 46% per patient, translating to annual reductions of $30,000 to $50,000. These savings are achieved by eliminating the buy-and-bill margins typical of hospital-based care.

Under the new model, a dedicated Nurse Navigator oversees the entire process, including site selection, scheduling, and insurance authorizations. Patients often spend up to six hours during hospital visits, frequently losing full workdays. World Class Health aims to mitigate this by offering evening and weekend appointments, allowing employees to maintain their schedules while receiving identical clinical standards. CEO Sid Nambiar stated that the initiative removes the friction of navigating complex healthcare logistics, ensuring members remain on therapy while employers avoid the higher costs associated with traditional hospital outpatient benchmarks.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!